These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Paschka P; Marcucci G; Ruppert AS; Whitman SP; Mrózek K; Maharry K; Langer C; Baldus CD; Zhao W; Powell BL; Baer MR; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD J Clin Oncol; 2008 Oct; 26(28):4595-602. PubMed ID: 18559874 [TBL] [Abstract][Full Text] [Related]
26. The Prognostic Relevance of BAALC and ERG Expression Levels in Cytogenetically Normal Pediatric Acute Myeloid Leukemia. Aref S; Al Khodary T; Zeed TA; El Sadiek A; El Menshawy N; Al Ashery R Indian J Hematol Blood Transfus; 2015 Mar; 31(1):21-8. PubMed ID: 25548440 [TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype. El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678 [TBL] [Abstract][Full Text] [Related]
28. The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia. Xiang L; Li M; Liu Y; Cen J; Chen Z; Zhen X; Xie X; Cao X; Gu W Ann Hematol; 2013 Aug; 92(8):1063-9. PubMed ID: 23515710 [TBL] [Abstract][Full Text] [Related]
29. Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia. Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH Leuk Lymphoma; 2014 Jan; 55(1):110-20. PubMed ID: 23647058 [TBL] [Abstract][Full Text] [Related]
31. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia. Shi JL; Fu L; Wang WD Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662 [TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes. Thol F; Yun H; Sonntag AK; Damm F; Weissinger EM; Krauter J; Wagner K; Morgan M; Wichmann M; Göhring G; Bug G; Ottmann O; Hofmann WK; Schambach A; Schlegelberger B; Haferlach T; Bowen D; Mills K; Ganser A; Heuser M Ann Hematol; 2012 Aug; 91(8):1221-33. PubMed ID: 22488406 [TBL] [Abstract][Full Text] [Related]
34. Overexpression of BAALC: clinical significance in Chinese de novo acute myeloid leukemia. Zhou JD; Yang L; Zhang YY; Yang J; Wen XM; Guo H; Yao DM; Ma JC; Chen Q; Lin J; Qian J Med Oncol; 2015 Jan; 32(1):386. PubMed ID: 25428390 [TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of combined BAALC and MN1 gene expression level in acute myeloid leukemia with normal karyotype. Marjanovic I; Karan-Djurasevic T; Kostic T; Virijevic M; Vukovic NS; Pavlovic S; Tosic N Int J Lab Hematol; 2021 Jun; 43(3):433-440. PubMed ID: 33242229 [TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Schwind S; Maharry K; Radmacher MD; Mrózek K; Holland KB; Margeson D; Whitman SP; Hickey C; Becker H; Metzeler KH; Paschka P; Baldus CD; Liu S; Garzon R; Powell BL; Kolitz JE; Carroll AJ; Caligiuri MA; Larson RA; Marcucci G; Bloomfield CD J Clin Oncol; 2010 Dec; 28(36):5257-64. PubMed ID: 21079133 [TBL] [Abstract][Full Text] [Related]
37. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients. Damiani D; Tiribelli M; Franzoni A; Michelutti A; Fabbro D; Cavallin M; Toffoletti E; Simeone E; Fanin R; Damante G Am J Hematol; 2013 Oct; 88(10):848-52. PubMed ID: 23760853 [TBL] [Abstract][Full Text] [Related]
38. Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia. Jinlong S; Lin F; Yonghui L; Li Y; Weidong W PLoS One; 2015; 10(2):e0118099. PubMed ID: 25646775 [TBL] [Abstract][Full Text] [Related]
39. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Whitman SP; Maharry K; Radmacher MD; Becker H; Mrózek K; Margeson D; Holland KB; Wu YZ; Schwind S; Metzeler KH; Wen J; Baer MR; Powell BL; Carter TH; Kolitz JE; Wetzler M; Moore JO; Stone RM; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD Blood; 2010 Nov; 116(18):3622-6. PubMed ID: 20656931 [TBL] [Abstract][Full Text] [Related]
40. Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients. Bou Samra E; Klein B; Commes T; Moreaux J Oncotarget; 2012 Aug; 3(8):824-32. PubMed ID: 22910040 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]